Cocrystal Pharma, Inc.
COCP
$1.02
$0.010.99%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -15.32% | 69.71% | |||
| Gross Profit | 29.22% | -69.71% | |||
| SG&A Expenses | 40.37% | -24.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.03% | 18.76% | |||
| Operating Income | 5.04% | -18.76% | |||
| Income Before Tax | 5.23% | -18.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.23% | -18.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.23% | -18.40% | |||
| EBIT | 5.04% | -18.76% | |||
| EBITDA | 5.02% | -18.88% | |||
| EPS Basic | 5.01% | 5.79% | |||
| Normalized Basic EPS | 5.10% | 5.75% | |||
| EPS Diluted | 5.01% | 5.79% | |||
| Normalized Diluted EPS | 5.10% | 5.75% | |||
| Average Basic Shares Outstanding | -0.20% | 25.68% | |||
| Average Diluted Shares Outstanding | -0.20% | 25.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||